ADAM-17: A target to increase chemotherapeutic efficacy in colorectal cancer?

Clinical Cancer Research

Volumn 16, Issue 13, 2010, Pages 3319-3321

  Lee, Adam M ^a   Diasio, Robert B ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GW 280264; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; GENE SILENCING; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT RESPONSE;

ADAM PROTEINS; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 77954232250     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1059     Document Type: Note

References (11)

1. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning JS, Longley DB, Johnston PG. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res 2010;16:3378-89.
2. SEER Cancer Statistics Review, 1975-2003. Bethesda (MD): National Cancer Institute.
3. Kuwai T, Nakamura T, Sasaki T, et al. Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis 2008;25:477-89.
4. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70. (Pubitemid 38579482)
5. Blobel CP. ADAMs: key components in EGFR signaling and development. Nat Rev Mol Cell Biol 2005;6:32-43.
6. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-33.
7. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733-6.
8. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010;45:146-69.
9. Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 2004;24:5172-83.
10. Merchant NB, Voskresensky I, Rogers CM, et al. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 2008;14:1182-91.
11. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-27.